| Bioactivity | Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models[1][2][3]. |
| Target | DLL4 |
| Invitro | Demcizumab (0-100 μg/mL) 结合人 DLL4 但不结合鼠 DLL4，并在 FACS 结合测定中阻断 DLL4 与 Notch1 受体的结合[3]。Demcizumab (20 μg/mL，48 小时) 降低 PDTALL 细胞中的 HES1 和 DTX1 mRNA 表达[4]。Demcizumab (0-80 μg/mL，1 或 2 或 3 天) 促进 PDTALL13 细胞死亡和早期凋亡[4]。 Cell Viability Assay[4] Cell Line: |
| In Vivo | Demcizumab (10 mg/kg，i.p.，每周一次) 联合 Irinotecan (7.5 mg/kg) 在 KRASWT 和 KRASMT CRC 异种移植模型中显示出显着的抗肿瘤作用[2].Demcizumab 单独或与伊立替康 (7.5 mg/kg) 联合使用对 OMP-C8 结肠肿瘤有效[3]。Demcizumab (20 mg/kg/周，腹腔注射) 增加注射了 PDTALL13 细胞的受辐照 NRG 小鼠的存活率[4]。 Animal Model: |
| Name | Demcizumab |
| CAS | 1243262-17-0 |
| Molar Mass | 145.65 (kDa) |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Smith DC, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014 Dec 15;20(24):6295-303. [2]. Fischer M, et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 2011;71:1520-5. [3]. Hoey T, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168–77. [4]. Xiong H, et al. Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. Theranostics. 2021 Jan 1;11(4):1594-1608. |